Moxastine

Last updated

Moxastine
Moxastine.png
Clinical data
AHFS/Drugs.com International Drug Names
ATC code
  • none
Identifiers
  • 2-[1,1-di(phenyl)ethoxy]-N,N-dimethylethanamine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard 100.020.626 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C18H23NO
Molar mass 269.388 g·mol−1
3D model (JSmol)
  • CC(C1=CC=CC=C1)(C2=CC=CC=C2)OCCN(C)C
  • InChI=1S/C18H23NO/c1-18(20-15-14-19(2)3,16-10-6-4-7-11-16)17-12-8-5-9-13-17/h4-13H,14-15H2,1-3H3 X mark.svgN
  • Key:BBIMHFSPNXQFAH-UHFFFAOYSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Moxastine (also known as mephenhydramine) is an antihistamine and anticholinergic. [1]

It was developed in Czechoslovakia [2] and sold in hydrochloride form as an antihistamine (Alfadryl).

It is, with 8-chlorotheophylline, a component of cocrystal/salt moxastine teoclate (mephenhydrinate) used as antiemetic (Theadryl; Kinedryl (with caffeine)).

Related Research Articles

H1 antagonists, also called H1 blockers, are a class of medications that block the action of histamine at the H1 receptor, helping to relieve allergic reactions. Agents where the main therapeutic effect is mediated by negative modulation of histamine receptors are termed antihistamines; other agents may have antihistaminergic action but are not true antihistamines.

<span class="mw-page-title-main">Loratadine</span> Antihistamine medication

Loratadine, sold under the brand name Claritin among others, is a medication used to treat allergies. This includes allergic rhinitis and hives. It is also available in drug combinations such as loratadine/pseudoephedrine, in which it is combined with pseudoephedrine, a nasal decongestant. It is taken orally.

<span class="mw-page-title-main">Hydroxyzine</span> Antihistamine drug

Hydroxyzine, sold under the brand names Atarax and Vistaril among others, is an antihistamine medication. It is used in the treatment of itchiness, anxiety, insomnia, and nausea. It is used either by mouth or injection into a muscle.

<span class="mw-page-title-main">Cetirizine</span> Antihistamine medication

Cetirizine is a second-generation antihistamine used to treat allergic rhinitis, dermatitis, and urticaria (hives). It is taken by mouth. Effects generally begin within thirty minutes and last for about a day. The degree of benefit is similar to other antihistamines such as diphenhydramine, which is a first-generation antihistamine.

<span class="mw-page-title-main">Doxylamine</span> First-generation antihistamine used as a short-term sedative and hypnotic (sleep aid)

Doxylamine is an antihistamine medication used to treat insomnia and allergies, and—in combination with pyridoxine (vitamin B6)—to treat morning sickness in pregnant women. It is available over-the-counter and is typically sold under such brand names as Equate, Unisom, or ZzzQuil, among others; and it is used in nighttime cold medicines (e.g., NyQuil) and pain medications containing acetaminophen and/or codeine to help with sleep. The medication is delivered chemically by the salt doxylamine succinate and is taken by mouth. Doxylamine and other first-generation antihistamines are the most widely used sleep medications in the world.Typical side effects of doxylamine (at recommended doses) include dizziness, drowsiness, grogginess, and dry mouth, among others.

<span class="mw-page-title-main">Orphenadrine</span> Muscle relaxant drug

Orphenadrine is an anticholinergic drug of the ethanolamine antihistamine class; it is closely related to diphenhydramine. It is a muscle relaxant that is used to treat muscle pain and to help with motor control in Parkinson's disease, but has largely been superseded by newer drugs. It is considered a dirty drug due to its multiple mechanisms of action in different pathways. It was discovered and developed in the 1940s.

<span class="mw-page-title-main">Ketotifen</span> Antihistamine medication

Ketotifen is an antihistamine medication and a mast cell stabilizer used to treat allergic conditions such as conjunctivitis, asthma, and urticaria (hives). Ketotifen is available in ophthalmic and oral forms: the ophthalmic form relieves eye itchiness and irritation associated with seasonal allergies, while the oral form helps prevent systemic conditions such as asthma attacks and allergic reactions. In addition to treating allergies, ketotifen has shown efficacy in managing systemic mast cell diseases such as mastocytosis and mast cell activation syndrome (MCAS), which involve abnormal accumulation or activation of mast cells throughout the body. Ketotifen is also used for other allergic-type conditions like atopic dermatitis (eczema) and food allergies.

<span class="mw-page-title-main">Phenacemide</span> Anticonvulsant

Phenacemide, also known as phenylacetylurea, is an anticonvulsant of the ureide (acetylurea) class. It is a congener and ring-opened analogue of phenytoin, and is structurally related to the barbiturates and to other hydantoins. Phenacemide was introduced in 1949 for the treatment of epilepsy, but was eventually withdrawn due to toxicity.

<span class="mw-page-title-main">Pheneturide</span> Chemical compound

Pheneturide, also known as phenylethylacetylurea, is an anticonvulsant of the ureide class. Conceptually, it can be formed in the body as a metabolic degradation product from phenobarbital. It is considered to be obsolete and is now seldom used. It is marketed in Europe, including in Poland, Spain and the United Kingdom. Pheneturide has a similar profile of anticonvulsant activity and toxicity relative to phenacemide. As such, it is only used in cases of severe epilepsy when other, less-toxic drugs have failed. Pheneturide inhibits the metabolism and thus increases the levels of other anticonvulsants, such as phenytoin.

<span class="mw-page-title-main">Chlorcyclizine</span> Chemical compound

Chlorcyclizine is a first-generation antihistamine of the diphenylmethylpiperazine group marketed in the United States and certain other countries. It is used primarily to treat allergy symptoms such as rhinitis, urticaria, and pruritus, and may also be used as an antiemetic. In addition to its antihistamine effects, chlorcyclizine has some anticholinergic, antiserotonergic, and local anesthetic properties. It has been studied as a potential treatment for various flaviviruses like hepatitis C and Zika virus.

<span class="mw-page-title-main">Tripelennamine</span> Chemical compound

Tripelennamine, sold under the brand name Pyribenzamine by Novartis, is a drug that is used as an antipruritic and first-generation antihistamine. It can be used in the treatment of asthma, hay fever, rhinitis, and urticaria, but is now less common as it has been replaced by newer antihistamines. The drug was patented at CIBA, which merged with Geigy into Ciba-Geigy, and eventually becoming Novartis.

<span class="mw-page-title-main">Suprofen</span> Non-steroidal anti-inflammatory drug

Suprofen is a nonsteroidal anti-inflammatory drug (NSAID) developed by Janssen Pharmaceutica that was marketed as 1% eye drops under the trade name Profenal.

<span class="mw-page-title-main">Bamipine</span> Chemical compound

Bamipine (trade name Soventol) is a pharmaceutical drug acting as an H1 antihistamine with anticholinergic properties. It is used as an antipruritic ointment. No oral use is known.

<span class="mw-page-title-main">Antihistamine</span> Drug that blocks histamine or histamine agonists

Antihistamines are drugs which treat allergic rhinitis, common cold, influenza, and other allergies. Typically, people take antihistamines as an inexpensive, generic drug that can be bought without a prescription and provides relief from nasal congestion, sneezing, or hives caused by pollen, dust mites, or animal allergy with few side effects. Antihistamines are usually for short-term treatment. Chronic allergies increase the risk of health problems which antihistamines might not treat, including asthma, sinusitis, and lower respiratory tract infection. Consultation of a medical professional is recommended for those who intend to take antihistamines for longer-term use.

<span class="mw-page-title-main">Piperoxan</span> Chemical compound

Piperoxan, also known as benodaine, was the first antihistamine to be discovered. This compound, derived from benzodioxan, was prepared in the early 1930s by Daniel Bovet and Ernest Fourneau at the Pasteur Institute in France. Formerly investigated by Fourneau as an α-adrenergic-blocking agent, they demonstrated that it also antagonized histamine-induced bronchospasm in guinea pigs, and published their findings in 1933. Bovet went on to win the 1957 Nobel Prize in Physiology or Medicine for his contribution. One of Bovet and Fourneau's students, Anne-Marie Staub, published the first structure–activity relationship (SAR) study of antihistamines in 1939. Piperoxan and analogues themselves were not clinically useful due to the production of toxic effects in humans and were followed by phenbenzamine (Antergan) in the early 1940s, which was the first antihistamine to be marketed for medical use.

<span class="mw-page-title-main">Phenbenzamine</span> Chemical compound

Phenbenzamine, sold under the brand name Antergan and known by the former developmental code name RP-2339, is an antihistamine of the ethylenediamine class which also has anticholinergic properties. It was introduced in 1941 or 1942 and was the first antihistamine to be introduced for medical use. Soon following its introduction, phenbenzamine was replaced by another antihistamine of the same class known as mepyramine. Following this, other antihistamines, such as diphenhydramine, promethazine, and tripelennamine, were developed and introduced. Owing to their sedative effects, phenbenzamine and promethazine were assessed in the treatment of manic depression in France in the 1940s and were regarded as promising therapies for such purposes. Whereas phenbenzamine was the first clinically useful antihistamine, piperoxan was the first compound with antihistamine properties to be discovered and was synthesized in the early 1930s.

<span class="mw-page-title-main">Etodroxizine</span> Chemical compound

Etodroxizine (INN) is a first-generation antihistamine of the diphenylmethylpiperazine group which is used as a sedative/hypnotic drug in Europe and South Africa.

Sushil Kumar Saxena is an Indian musicologist, academic, scholar and the author of several books on music, philosophy and aesthetics. He is a former member of the faculty of the University of Delhi and has served the University Court as a member. His works include Studies in the Metaphysics of Bradley, Hindustan Music and Aesthetics Today, Art and Philosophy: Seven Aestheticians, Croce, Dewey, Collingwood, Santayana, Ducasse Langer, Reid, and Swinging Syllables Aesthetics of Kathak Dance and his lectures have been included in a book, Indian Music: Eminent Thinkers on Core Issues ; Discourses by Premlata Sharma, S. K. Saxena and Kapila Vatsyayan. He is a recipient of the Sangeet Natak Akademi Fellowship which he received in 2007. The Government of India awarded him the third highest civilian honour of the Padma Bhushan, in 2008, for his contributions to Indian music.

<span class="mw-page-title-main">Dianol</span> Chemical compound

Dianol is a synthetic, nonsteroidal estrogen that was never marketed. It is a dimer and impurity of anol, and was, along with hexestrol, involved in erroneous findings of highly potent estrogenic activity with anol. Although a potent estrogen, it requires a dose of 100 μg to show activity, whereas hexestrol shows activity with a mere dose of 0.2 μg.

<span class="mw-page-title-main">Ro 6-3129</span> Chemical compound

Ro 6-3129, also known as 16α-ethylthio-6-dehydroretroprogesterone or as 16α-ethylthio-9β,10α-pregna-4,6-diene-3,20-dione, as well as 16α-ethylthiodydrogesterone, is a progestogen of the retroprogesterone group which was developed by Roche but was never marketed. It shows greater potency than dydrogesterone in bioassays.

References

  1. Saxena AK, Saxena M (1992). "Developments in antihistamines (H1)". In Jucker E (ed.). Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. pp. 35–125. doi:10.1007/978-3-0348-7144-0_3. ISBN   978-3-0348-7146-4.
  2. Wardell WM (1978). Controlling the Use of Therapeutic Drugs An International Comparison. Washington, D.C: American Enterprise Institute for Public Policy Research. p. 242. ISBN   978-0-8447-3278-7.

See also